Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksUniphar Regulatory News (UPR)

Share Price Information for Uniphar (UPR)

Share Price is delayed by 15 minutes
Get Live Data
393.00    0.00 (0.00%)
Bid:
390.00
Ask:
396.00
Spread: 6.00 (1.538%)
Market Cap: £1.02b
UPR Live PriceLast checked at - London Stock Exchange

Intraday Uniphar Share Chart

AGM Results

8 May 2025 14:09

RNS Number : 9370H
Uniphar PLC
08 May 2025
 

AGM Results

 

Dublin, London | 8 May 2025

 

Uniphar plc (the Company) is pleased to announce that at its Annual General Meeting held at 11.00 a.m. today, 8 May 2025, each of the resolutions set out in the Notice of Annual General Meeting circulated to shareholders and made available on the Company's website, www.uniphar.ie, were duly passed without amendment.

Details of votes cast are set out below:

 

 

RESOLUTION

For

For %

Against

Against

%

Withheld

1

Financial Statements and Reports

153,243,069

99.17%

1,278,544

0.83%

132,837

2

Final Dividend of

€3.4m

154,654,450

100.00%

0

0.00%

0

3(a)

Re-elect Ger Rabbette

153,894,576

99.51%

759,874

0.49%

0

3(b)

Re-elect Tim Dolphin

153,864,527

99.51%

761,647

0.49%

28,276

3(c)

Re-elect Paul Hogan

154,120,862

99.65%

533,588

0.35%

0

3(d)

Re-elect Sue Webb

153,923,147

99.55%

703,027

0.45%

28,276

3(e)

Re-elect Jim Gaul

146,614,423

94.80%

8,040,027

5.20%

0

3(f)

Re-elect Liz Hoctor

154,548,421

99.93%

106,029

0.07%

0

3(g)

Re-elect Maurice Pratt

151,621,344

98.04%

3,032,306

1.96%

800

3(h)

Re-elect Valerie Sick

154,335,546

99.79%

318,904

0.21%

0

4

Remuneration of Auditors

111,340,592

92.64%

8,849,615

7.36%

34,464,243

5

Authority to allot relevant securities

129,854,034

83.96%

24,800,416

16.04%

0

6

Disapplication of pre- emption rights in

specified circumstances

153,651,591

99.35%

1,002,859

0.65%

0

7

Disapplication of pre- emption rights in additional

circumstances

124,033,872

80.46%

30,127,960

19.54%

492,618

8

Authorise market purchases of the Company's Ordinary Shares

154,058,953

100.00%

0

0.00%

595,497

9

Re-issuance of Treasury Shares

154,654,450

100.00%

0

0.00%

0

 

 

--- ENDS ---

Contact details

Uniphar Group

 

Tel: +353 (0) 1 428 7777

Allan Smylie, Head of Strategy and IR

Davy (Joint Corporate Broker, Nominated Advisor and

Euronext Growth Listing Sponsor)

 

Tel: +353 (0) 1 679 6363

Daragh O'Reilly

Niall Gilchrist

Ivan Murphy

RBC Capital Markets (Joint Corporate Broker)

 

Tel: +44 (0) 20 7653 4000

Jamil Miah

Rupert Walford

Stifel Nicolaus Europe Limited (Joint Corporate Broker)

 

Tel: +44 (0) 20 7710 7600

Matt Blawat

Ben Maddison

Francis North

Q4 PR

 

Tel: +353 (0) 1 475 1444

Iarla Mongey, Public Relations Advisor to Uniphar Group

 

 

About Uniphar plc 

Headquartered in Dublin, Ireland, the Uniphar Group is an international diversified healthcare services business servicing the requirements of more than 200 multinational pharmaceutical and medical technology manufacturers across three divisions - Uniphar Medtech, Uniphar Pharma and Uniphar Supply Chain & Retail. The Group is active in Europe, North America, APAC and MENA and delivers to 160+ countries.

 

Uniphar solves problems for healthcare. We sit in the middle between the manufacturers and their stakeholders, and we help them both to overcome the problems of a new, complicated healthcare environment. The Company's vision is to improve patient access to pharmaco-medical products and treatments by enhancing connectivity between manufacturers and healthcare professionals and their patients. Uniphar represents a strong combination of scale, growth, and profitability.

 

Uniphar Medtech

Uniphar Medtech is a leading pan-European medical device distributor and solutions partner. The Group's strategy for Uniphar Medtech is to grow our service offering across Europe and expand our addressable market by serving new specialities and new manufacturers.

 

Uniphar Pharma

Uniphar Pharma operates a global business with high value services across the lifecycle of a pharmaceutical product. We enable pharma and biotech companies to bring innovative medicines to global markets and provide healthcare professionals with access to medicines they cannot source through traditional channels. Our strategy is to build a leading platform to provide the specialist support and expertise needed to improve access to these medicines.

 

Uniphar Supply Chain & Retail

Uniphar Supply Chain & Retail is the leading pharmaceutical wholesaler in Ireland with a growing symbol group offering of retail pharmacies. The Group's strategy for Uniphar Supply Chain & Retail is to grow our wholesale market share, our symbol group network and our own brand, in-licenced and consumer products portfolio.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGMPKFBKNBKDOPK
Date   Source Headline
27th Feb 20257:00 amRNSTransaction in Own Shares
26th Feb 20259:30 amRNSExecutive Restricted Share Plan Dealings
26th Feb 20257:05 amRNSLaunch of €35m Share Buyback Programme
25th Feb 20257:00 amRNS2024 Preliminary Results
28th Jan 20257:00 amRNSFull Year Trading Update and Notice of Results
16th Dec 20249:00 amRNSHolding(s) in Company
2nd Dec 20249:00 amRNSDirector/PDMR Shareholding
29th Nov 20244:45 pmRNSHolding(s) in Company
3rd Sep 20247:00 amRNS2024 Interim Results
30th Jul 20247:00 amRNSHalf Year Trading Update and Notice of Results
24th Jun 202412:30 pmRNSHolding(s) in Company
21st May 20247:00 amRNSDirector/PDMR Shareholding
17th May 20242:15 pmRNSHolding(s) in Company
9th May 20242:30 pmRNSAGM Results
9th May 20247:00 amRNSAGM Statement
26th Apr 20241:48 pmRNSHolding(s) in Company
15th Apr 20249:00 amRNSDirector/PDMR Shareholding
5th Apr 20247:00 amRNSNotice of AGM & Annual Report
27th Feb 20247:00 amRNS2023 Preliminary Results
6th Feb 202410:30 amRNSHolding(s) in Company
30th Jan 20247:00 amRNSDirectorate Change
30th Jan 20247:00 amRNSFull Year Trading Update and Notice of Results
17th Jan 20247:00 amRNSDirectorate Change
24th Nov 202311:20 amRNSHolding(s) in Company
9th Oct 202311:00 amRNSDirector/PDMR Shareholding
6th Oct 20237:00 amRNSDirector/PDMR Shareholding
4th Oct 20237:00 amRNSDirector/PDMR Shareholding
21st Sep 20233:33 pmRNSHolding(s) in Company
19th Sep 20239:29 amRNSHolding(s) in Company
14th Sep 20233:00 pmRNSHolding(s) in Company
14th Sep 20237:00 amRNS2023 Interim Results
4th Sep 20237:00 amRNSHolding(s) in Company
1st Aug 20232:45 pmRNSHolding(s) in Company
26th Jul 20237:00 amRNSHalf Year Trading Update and Notice of Results
14th Jun 20235:00 pmRNSHolding(s) in Company
11th May 20233:32 pmRNSAGM Results
11th May 20237:00 amRNSAGM Statement
3rd May 20237:00 amRNSHolding(s) in Company
6th Apr 20237:00 amRNSNotice of AGM & Annual Report & Dividend Update
3rd Mar 20237:00 amRNSExecutive Restricted Share Plan Dealings
1st Mar 20233:00 pmRNSDirector/PDMR Shareholding
28th Feb 20237:00 amRNS2022 Preliminary Results
3rd Feb 20237:00 amRNSHolding(s) in Company
2nd Feb 20237:00 amRNSCompletion of McCauley Acquisition
31st Jan 20237:00 amRNSFull Year Trading Update and Notice of Results
25th Jan 20237:00 amRNSHolding(s) in Company
16th Dec 20227:00 amRNSNavi acquisition not cleared by CCPC
8th Dec 20224:06 pmRNSHolding(s) in Company
2nd Dec 20227:00 amRNSNew Share Option Plan
21st Nov 20227:00 amRNSAcquisition of BModesto Group

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.